Compare STXS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | UNCY |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 145.3M |
| IPO Year | 2004 | 2021 |
| Metric | STXS | UNCY |
|---|---|---|
| Price | $1.30 | $4.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.00 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,346,617.00 | $675,000.00 |
| Revenue This Year | $28.22 | N/A |
| Revenue Next Year | $30.47 | $582.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.24 | $3.72 |
| 52 Week High | $3.59 | $8.74 |
| Indicator | STXS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 32.44 | 40.57 |
| Support Level | N/A | $4.28 |
| Resistance Level | $1.97 | $5.39 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 10.16 | 20.26 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.